 "India could get its fourth vaccine by August, says NITI Aayog's V K Paul")
India could have a fourth Covid vaccine by August with Hyderabad-based Biological E’s candidate having completed its phase one and two trials and about to enter stage three, V K Paul, member-health, NITI Aayog, told reporters on Wednesday.
Besides, Covishield and Covaxin, which are available in India, regulator Drugs Controller General of India (DCGI) has also approved Russia’s Sputnik V.
Paul said that the vaccine was being developed with the help of the department of biotechnology and the company has a capacity to make around 70 million doses per month. “It is a significant development. They are old manufacturers of children’s vaccines and have a major capacity,” Paul said, adding that Biological E will be submitting data of phase one and two clinical trials soon.
When contacted, Biological E did not comment. The Hyderabad-based vaccine major is gearing up to make 1.5 billion doses of multiple candidates of Covid-19 vaccines: One billion for Texas-based Baylor College of Medicine (BCM)'s recombinant protein vaccine candidate and about 500 million doses for Johnson & Johnson (J&J) unit Janssen Pharmaceutical's vaccine candidate. Last October, Mahima Datla, managing director (MD) of Biological E had told Business Standard, “We used the pichia pastoris (a yeast) platform to express BCM’s candidate. We have experience of large scale manufacturing using this platform, having supplied millions of doses and we could scale up easily.”
She added that one of the advantages of this candidate is that it is easy to scale up.
“The United States, through the DFC (Development Finance Corporation), will work with Biological E, to finance increased capacity to support Biological E’s effort to produce at least one billion doses of Covid-19 vaccines by the end of 2022 with Stringent Regulatory Authorization (SRA) and/or World Health Organization (WHO) Emergency Use Listing (EUL), including the Johnson & Johnson vaccine,” a White House statement had said sometime back. xPaul also said the government was making a renewed effort to talk to global suppliers and manufacturers of vaccines. “We are in active talks with major suppliers along with domestic vaccine makers. The policy has become more liberal from their point of view now,” Paul added.
Besides, Covishield and Covaxin, which are available in India, regulator Drugs Controller General of India (DCGI) has also approved Russia’s Sputnik V.
Paul said that the vaccine was being developed with the help of the department of biotechnology and the company has a capacity to make around 70 million doses per month. “It is a significant development. They are old manufacturers of children’s vaccines and have a major capacity,” Paul said, adding that Biological E will be submitting data of phase one and two clinical trials soon.
When contacted, Biological E did not comment. The Hyderabad-based vaccine major is gearing up to make 1.5 billion doses of multiple candidates of Covid-19 vaccines: One billion for Texas-based Baylor College of Medicine (BCM)'s recombinant protein vaccine candidate and about 500 million doses for Johnson & Johnson (J&J) unit Janssen Pharmaceutical's vaccine candidate. Last October, Mahima Datla, managing director (MD) of Biological E had told Business Standard, “We used the pichia pastoris (a yeast) platform to express BCM’s candidate. We have experience of large scale manufacturing using this platform, having supplied millions of doses and we could scale up easily.”
She added that one of the advantages of this candidate is that it is easy to scale up.
“The United States, through the DFC (Development Finance Corporation), will work with Biological E, to finance increased capacity to support Biological E’s effort to produce at least one billion doses of Covid-19 vaccines by the end of 2022 with Stringent Regulatory Authorization (SRA) and/or World Health Organization (WHO) Emergency Use Listing (EUL), including the Johnson & Johnson vaccine,” a White House statement had said sometime back. xPaul also said the government was making a renewed effort to talk to global suppliers and manufacturers of vaccines. “We are in active talks with major suppliers along with domestic vaccine makers. The policy has become more liberal from their point of view now,” Paul added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%